Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EGCG, Hyaluronic Acid, Folic Acid and Vitamin B12 for HPV-Positive Cervical Lesions
NCT06098456Phase 2Completed
- Sponsor
- Centro di Ricerca Clinica Salentino
- Start
- Nov 2023
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of epigallocatechin gallate + folic acid + vitamin B12 + hyaluronic acid in human papillomavirus infection and Squamous Intraepithelial Lesion of the Cervix (SIL) (2 arms), sponsored by Centro di Ricerca Clinica Salentino. Primary endpoint: Positivity to HPV infection at 6 months. Started Nov 2023; status: completed.
02
Drugs
epigallocatechin gallate + folic acid + vitamin B12 + hyaluronic acid
03
Conditions
human papillomavirus infectionSquamous Intraepithelial Lesion of the Cervix (SIL)
Beyond the preview
Go deeper on NCT06098456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06098456.